CIPLA2019-04-012019-06-30in-bse-fin:OneOperatingExpenses01Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentRevenue01Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentRevenue02Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentResults01Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentResults02Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentAssets01Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentAssets02Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentLiabilities01Member CIPLA2019-06-30in-bse-fin:OneReportableSegmentLiabilities01Member CIPLA2019-04-012019-06-30in-bse-fin:OneReportableSegmentLiabilities02Member CIPLA2019-06-30in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares CIPLA 2019-04-01 2020-03-31 2019-07-15 INR Crores First quarter Multi segment 2019-04-01 2019-06-30 Unaudited Consolidated 39890200000.00 783700000.00 40673900000.00 11044800000.00 3686600000.00 -2768200000.00 7561300000.00 521200000.00 2680000000.00 11319300000.00 34045000000.00 6628900000.00 0.00 6628900000.00 2907900000.00 -985500000.00 1922400000.00 0.00 4706500000.00 0.00 0.00 0.00 -235000000.00 4471500000.00 -2800000.00 4468700000.00 4781900000.00 -310400000.00 4782400000.00 -313700000.00 1611700000.00 2 5.93 5.93 0.00 0.00 5.93 5.93 1. The financial results have been prepared in accordance with Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI Listing Regulations. n2. Effective 1.4.2019, the Group has adopted Ind AS 116 Leases using the modified retrospective method. The Group has applied the standard to its leases with the cumulative impact recognised on the date of initial application (1.4.2019). Accordingly, previous period information has not been restated. n(In lieu of character restriction please refer point no. 2 of scanned .pdf consolidated results uploaded on 07.08.2019 for further details) n3. The Company had received various notices of demand from the NPPA, GoI, on account of alleged overcharging in respect of certain drugs under the Drugs (Prices Control) Orders. The total demand against the Company as stated in NPPA public disclosure amounts to Rs. 2,655.14 Crore. n(In lieu of character restriction please refer point no. 3 of scanned .pdf results uploaded on 07.08.2019 for further details) n4. The paid-up equity share capital stands increased to Rs. 161.17 Crore (80,58,28,425 equity shares of Rs. 2 each) upon allotment of 1,27,159 equity shares of Rs. 2 each pursuant to ESOS 2013-A during the quarter ended 30.06.2019. n5. On 24.4.2019, the Company's wholly owned subsidiary Cipla Medpro South Africa (Pty) Limited has acquired 30% stake in Brandmed (Pty) Limited ( Brandmed ) for a total consideration of Rs. 31.61 Crore (ZAR 65 million). As at 30.06.2019 investment in Brandmed is accounted as Investment in Associate as per Ind AS 28 Investments in Associates and Joint Ventures and Ind AS 112 – Disclosures of Interests in Other Entities. The Group has reported the investments based on initial determination of the net fair values of investee’s assets and liabilities. n6. The Unaudited Standalone financial results for the quarter ended 30.06.2019 are available on the Company’s website (www.cipla.com) under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com. The key standalone financial information is as under: n nttttttttttRs in Crores nttttttQuarter endedt tYear ended nParticularstt t30-06-2019t31-03-2019t30-06-2018t31-03-2019 nttttUnauditedtAuditedt UnauditedtAudited ntttttt(Refer note8) n nTotal revenue from operationst3,229.33t 3,456.53t 2,987.57t 12,374.01 nProfit before taxttt978.33tt832.96tt524.93tt2,492.83 nProfit after taxttt694.00tt634.07tt390.55tt1,888.41 n n7. The figures of the previous year/period have been regrouped/recast to render them comparable with the figures of the current period. n8. The figures for the quarter ended 31.03.2019 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months ended 31.12.2018. n9. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 7th August, 2019. These results have been subjected to limited review by statutory auditors. Other Expenses 11319300000.00 New Ventures 362400000.00 Pharmaceuticals 39599300000.00 71500000.00 New Ventures -191500000.00 Pharmaceuticals 7341600000.00 521200000.00 0.00 Segment Assets and Liabililties : nAs certain assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table. New Ventures 0.00 Pharmaceuticals 0.00 0.00 New Ventures 0.00 Pharmaceuticals 0.00 0.00